Abstract
Detection of clinical isolates of Pseudomonas aeruginosa producing metallo-𝛽-lactamases (MBL) and extended-spectrum 𝛽-lactamases (ESBL) is essential to adequately treat patients and control the spread of resistance. We investigated the frequency of carbapenem resistance mediated by acquired 𝛽-lactamases in P. aeruginosa isolates from a tertiary cancer hospital in Bulgaria. The prevalence of P. aeruginosa infec¬tions was relatively low - approximately 2% of all hospital-acquired infections, while the carbapenem re¬sistance rate was estimated at 25% in 2023. Carbapenem resistance due to VIM and NDM MBL types was observed in 8/54 (14.81%) isolates. PER, VEB, or GES ESBLs were detected in a total of 8/54 (14.81%) isolates including 3 isolates co-harbouring NDM and GES enzymes. The overall frequency of 24.07% (13/54) of acquired carbapenemase and ESBL genes in our study reflects the multicomponent nature of carbapenem resistance in P. aeruginosa and highlights the need for reliable screening.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.